Lomitapide

Lomitapide is an oral lipid‑lowering agent that acts as an inhibitor of microsomal triglyceride transfer protein (MTP). It is primarily indicated for the treatment of homozygous familial hypercholesterolemia (HoFH), a rare genetic disorder characterized by markedly elevated low‑density lipoprotein cholesterol (LDL‑C) levels.

Chemical and Pharmacological Profile

• IUPAC name: (2S,3R,4R,5S,6R)-2‑[(2R,4R)-2‑hydroxy‑4‑(2‑hydroxy‑4‑methoxy‑phenyl)‑6‑methylhept‑5‑enyl]‑4‑hydroxy‑6‑(hydroxymethyl)oxane‑3‑yl 2‑(2‑hydroxy‑5‑methoxyphenyl)acetate
• Molecular formula: C₃₇H₅₈O₁₁
• Molecular weight: 709.93 g/mol
• Route of administration: Oral tablets (commonly 5 mg, 10 mg, 20 mg doses)

Mechanism of Action

Lomitapide binds to MTP, a protein essential for the assembly and secretion of apolipoprotein B‑containing lipoproteins (VLDL in the liver and chylomicrons in the intestine). By inhibiting MTP, lomitapide reduces the hepatic production of VLDL, leading to a downstream decrease in circulating LDL‑C concentrations.

Medical Indications

• United States (FDA): Treatment of HoFH in patients ≥12 years of age, as an adjunct to a low‑fat diet, exercise, and other lipid‑lowering therapies (e.g., statins, ezetimibe).
• European Union (EMA): Same indication, with a recommended starting dose of 5 mg once daily, titrated up to a maximum of 60 mg per day based on tolerability and LDL‑C response.

Efficacy

Clinical trials (e.g., the phase III randomized, double‑blind study of lomitapide in HoFH) demonstrated:

• Mean reductions of 38–50 % in LDL‑C from baseline after 12 months of therapy, when combined with maximally tolerated statin therapy.
• Sustained LDL‑C lowering over longer follow‑up periods (up to 5 years) in observational extensions.

Safety and Adverse Effects

Common adverse events (≥10 % incidence) include:

• Gastrointestinal: Diarrhea, nausea, abdominal discomfort, dyspepsia.
• Hepatic: Elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST); routine monitoring of liver enzymes is required.
• Lipid‑related: Increases in hepatic fat content (hepatic steatosis) detected by imaging; recommended dietary fat restriction (<20 % of total caloric intake) mitigates this risk.

Contraindications and cautions:

• Active liver disease or unexplained persistent elevations in transaminases.
• Pregnancy: teratogenic potential; contraindicated. Effective contraception is required for women of childbearing potential.

Pharmacokinetics

• Absorption: Oral bioavailability is low; food, especially dietary fat, markedly increases absorption.
• Distribution: Highly protein‑bound (~99 %).
• Metabolism: Primarily metabolised by CYP3A4; concomitant strong CYP3A4 inhibitors increase exposure and are contraindicated.
• Elimination: Mean half‑life of approximately 30 hours; excreted mainly via feces.

Regulatory and Market Information

• Brand name: Juxtapid (U.S.), Lojuxta (EU).
• Approval dates: FDA approval in July 2012; EMA approval in August 2013.
• Patents and exclusivity: Original patents expired in the early 2020s; generic versions have entered some markets.

Clinical Considerations

• Dietary management: Patients must adhere to a low‑fat diet (≤20 % of calories) to reduce gastrointestinal side effects and hepatic fat accumulation.
• Drug interactions: Strong CYP3A4 inducers (e.g., rifampin, carbamazepine) decrease lomitapide exposure; such combinations should be avoided.
• Monitoring: Baseline and periodic liver function tests, fasting lipid panels, and assessment of hepatic steatosis (e.g., ultrasound or MRI) are recommended.

Research and Development

Ongoing investigations assess:

• Long‑term cardiovascular outcomes associated with sustained LDL‑C reduction by lomitapide.
• Combination therapy strategies with PCSK9 inhibitors for patients inadequately controlled on lomitapide plus statins/ezetimibe.

Summary

Lomitapide is an FDA‑ and EMA‑approved MTP inhibitor indicated for the adjunctive treatment of homozygous familial hypercholesterolemia. Clinical data support substantial LDL‑C lowering, but therapy requires careful dietary adherence, liver function monitoring, and attention to drug‑interaction potential.